期刊文献+

2000年~2002年广州地区抗感染药物应用频度分析 被引量:3

Analysis on Antiinfective Drug Utilization in Guangzhou Area During 2000~2002
暂未订购
导出
摘要 目的 :调查分析广州地区抗感染药物应用情况。方法 :采用DDD分析方法和金额排序法 ,对广州地区医院 2 0 0 0年~ 2 0 0 2年抗感染药物购入数据进行综合分析。结果 :3年来 ,头孢菌素类药金额平均占抗微生物药物总金额的 4 0 % ,占第 1位 ;拉米夫定在DDDs排序及金额排序中均从 2 0 0 0年的第 4位渐升至 2 0 0 2年的第 1位 ;在金额排序中排位在前面的一般为广谱、高效、新型的抗菌药物。结论 :该类药物的应用基本合理 ,但对广谱、高效、新型的抗感染药物仍存在不合理应用现象 。 OBJECTIVE:To investigate and analyze the utilization status of antiinfective drugs in Guangzhou. METHODS: To conduct a comprehensive study on those data of antibiotic drugs purchased by the hospitals in Guangzhou from 2000 to 2002 by using the methods of DDD analysis and ranking of sum of money. RESULTS: Cephalosporins had ranked first in terms of the amount of antibiotic drugs purchased since the last three years, amounting to 40% on average of total amount of antibiotic drugs purchased while ranking of Lamivudine from the 4th place in 2000 to the 1st place in 2002 in both of the DDDs list and the order of sum of money. In general, broad-spectrum, strong effective and new antibiotic drugs usually ranked first in the order of sum of money. CONCLUSION: The utilization of antibiotic drugs is basically reasonable, nevertheless, we should also pay attention to those broad-spectrum, strong effective and new antibiotic drugs with unreasonable utilization phenomenon.
出处 《中国医院用药评价与分析》 2004年第2期86-90,共5页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 2000年-2002年 广州市 抗感染药物 耐药菌株 antiinfective drugs medicine utilization analysis
  • 相关文献

参考文献3

二级参考文献56

  • 1Lawrence L E. Anti bacterial activity of BMS284756, a novel des - F(6) - quinolone, against Staphylococcus aureus stuains with topoisow, erase mutations [ J ]. J Antimicrob Chemther, 2001, 47 ( Suppl1):44.
  • 2Nagai K, Appelbaum P C, Davies T A, et al. Susceptibility to Telithromycin in 1,011 Streptococcus tryogenes Isolates from 10 Central and Eestem European Countries [ J ] .Antimicrob Agents Chemother,2002,46(2) : 546.
  • 3Nagai K, Appelbaum P C, Davies T A, et al. Susceptibility to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pnmanococci from 10 central and easten european countries [ J ]. Antimicrob Agents Chemother, 2002,46(2) :371.
  • 4Mitten M J, Meulbroek J, Nukkala M, et al. Efficacies of ABT - 773, a new ketolide, against experimental bacterial Infections [J].Antimicrob Agents Chemother,2001,45(9) : 2585.
  • 5Nilius A M,Bui MH, Almer L, et al. Comparative In vitro aerivity of ABT- 773, a novel antibacterial ketolide [ J ]. Antimicrob Agents Chemother,2001,45(7) : 2163.
  • 6Alexis D,Alain B.Novel fluoroketohdes: synthesis and antibacterial activity [J] .Drugs Future,2001,26(10) : 975.
  • 7Noviello S,Ianniello F,Esposito S. In vitro activity of LY - 333328 (oritavanein) against gram- positive aerobic Cocci and synergy with ciprofloxacin against Enterococci [J]. J Antimicrob chemother , 2001, 48(2) :283.
  • 8Anon.IB397 [J]. Drugs Future,2000,25(8):849.
  • 9Anon. IB397 [J]. Drugs Future,2001,26(8):796.
  • 10Anon. Daptomyein: cidecin, dapcin, LY146032 [J]. Drugs in R&D,2002,3(1) :33.

共引文献35

同被引文献16

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部